Genentech orphan status for CD4
Executive Summary
Firm receives orphan status from FDA for its recombinant soluble CD4 for AIDS. Genentech's Phase I trials on CD4 began in August and are ongoing at the National Cancer Institute, San Francisco General Hospital and New England Deaconess Hospital at Harvard. Firm says it is first to be granted orphan status for CD4.